Latest Conference Articles

First-in-Human Study of RO7122290 Shows Promise in Patients With Select Solid Tumors

Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.

Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Nivolumab/Cabozantinib Combo Doubles PFS in Frontline RCC

The combination of nivolumab and cabozantinib led to a 49% reduction in the risk of disease progression or death, while also significantly improving overall survival and doubling objective response rate, compared with sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.

Neoadjuvant Durvalumab Induces Responses in Resectable NSCLC, But High Postsurgical Mortality Ends Study

Neoadjuvant durvalumab achieved a satisfactory complete surgical resection rate in patients with resectable non–small cell lung cancer, demonstrating preliminary promise for this treatment strategy.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

Updated Data Shows Xevinapant Significantly Improves OS in Locally Advanced Head and Neck Cancer

Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.

Avelumab as Frontline Maintenance Improves OS Across Advanced Urothelial Carcinoma Subgroups

Frontline maintenance treatment with avelumab plus best supportive care improved both progression-free and overall survival compared with BSC alone across prespecified subgroups of patients with advanced or metastatic urothelial carcinoma that has not progressed on first-line platinum-based chemotherapy.

Despite Early Response, Frontline Avelumab Falls Short in Metastatic Urothelial Carcinoma

Despite observed responses, induction therapy with avelumab prior to standard of care gemcitabine/carboplatin fails to sustain clinically meaningful efficacy and is not an adequate strategy for the first-line treatment for patients with metastatic urothelial carcinoma.

Novel PD-1/PD-L1 Inhibitor Combo Promotes Antitumor Activity in Urothelial Carcinoma

The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.

Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian Cancer

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.

Ipatasertib/Chemotherapy Combo Falls Flat in HR+ HER2- Advanced Breast Cancer

The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

SYMPATICO Evaluates Frontline Ibrutinib and Venetoclax Combo in MCL

The open-label arm of the 3-part phase 3 SYMPATICO trial is evaluating the combination of ibrutinib and venetoclax in previously untreated patients with mantle cell lymphoma.

Genetic Counselor Addresses Common Questions About Testing in Oncology

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.

New Focus Needed on Preventing Brain Metastases in Early Breast Cancer

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

Sparano Shares Progress Made in the Molecular Guided Management of Breast Cancer

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy.

Deciphering DNA Repair Deficiency in Breast Cancer

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Health Equity for Patients With Cancer Requires Moving Conversation to Action

In order to achieve health equity for patients with cancer, physicians must first understand the root cause of heath disparities, many of which may be invisible.

Mitigating Racial Disparities in Oncology

Chasity M. Washington, MPH, CHES, discusses ways to mitigate racial disparities in oncology.

The Evolving Treatment Landscape in SCLC

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Managing Systemic Toxicities and Limiting Therapy Non-Adherence in Breast Cancer

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

Dr. Tripathy on Genomically Guided Therapy in Breast Cancer

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Chiang on Unanswered Questions With Immunotherapy in NSCLC

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Lara Shares Updates With Immunotherapy in Extensive-Stage SCLC

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

Osimertinib Results Show Potential for Earlier TKI Use in EGFR-Mutant NSCLC

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

Gandara Reflects on Current Status of TMB in NSCLC

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.